A Combination of Talazoparib and Enzalutamide Prolongs OS in Unselected and Patients with HRR-deficient mCRPC By Ogkologos - August 11, 2025 622 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the TALAPRO-2 study Source RELATED ARTICLESMORE FROM AUTHOR Clinical Activity of Talazoparib Plus Enzalutamide Demonstrated in Patients with High-Volume mHNPC, but Without Clear Benefit Over Enzalutamide in Biomarker-Unselected Population FDA Approves Daraxonrasib for Metastatic Pancreatic Adenocarcinoma Chemotherapy-Free Regimen of Targeted Agent and Immunotherapeutic Superior to Imatinib and Chemotherapy Among Adult Patients with Ph-positive ALL MOST POPULAR Six Years of Adjuvant Imatinib Improves DFS Over Three Years Treatment... September 11, 2024 Short-Term Radiotherapy with Preoperative Chemotherapy Followed by Surgery is Efficacious with... March 21, 2022 Miss New Jersey Collegiate USA Uses Her Prestigious Position to Shed... March 31, 2021 New Research in Treating Leukemia and Lymphoma: ASH Annual Meeting 2020 January 15, 2021 Load more HOT NEWS FDA Alters Approved Use of Two Checkpoint Inhibitors for Bladder Cancer What Are Multi-Cancer Early Detection Tests and How Might They Impact... Cancer in Lymph Nodes May Help Tumors Spread by Enlisting Immune... Adding Pembrolizumab to Docetaxel Does Not Significantly Improve Outcomes in Patients...
